ATRC

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

Max Max

About Atricure Inc

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
CEO
Employees
750
Headquarters

News

VRBPAC backs adding omicron-component to COVID-19 boosters
Jun 28, 2022 00:00am

FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted today to recommend the use of variant-specific boosters. Out of 21 voting members, 19 supported the use of a SARS-CoV-2 omicron component for COVID-19 booster vaccines. “I want to be clear that this doesn’t mean that we are saying that there will be boosters recommended for everyone…


Source:WTWH
3D Systems & EMS-GRILTECH enter strategic partnership to advance materials innovation
Jun 28, 2022 00:00am

3D Systems and EMS-GRILTECH announced they have entered into a strategic partnership to enhance additive manufacturing materials development. Combining 3D Systems’ expertise and leadership as an additive manufacturing solutions partner with EMS-GRILTECH’s (a Business Unit of EMS Group) expertise in the specialized manufacturing of polyamides has enabled the companies to introduce a novel nylon copolymer […]


Source:WTWH
NAHAD hosts nearly 900, establishes new committee structure at Annual Meeting
Jun 28, 2022 00:00am

Last month, nearly 900 attendees gathered for NAHAD’s 38th Annual Meeting and Convention at the Fontainebleau Miami Beach to reconnect with existing clients, engage with new customers, and take part in multiple educational sessions. The convention ran from May 15-18, and was kicked off with the “State of NAHAD” report by 2021-2022 by President Jeff […]


Source:WTWH
VRBPAC backs adding omicron-component to COVID-19 boosters
Jun 28, 2022 00:00am

FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted today to recommend the use of variant-specific boosters. Out of 21 voting members, 19 supported the use of a SARS-CoV-2 omicron component for COVID-19 booster vaccines. “I want to be clear that this doesn’t mean that we are saying that there will be boosters recommended for everyone…


Source:WTWH
NAHAD hosts nearly 900, establishes new committee structure at Annual Meeting
Jun 28, 2022 00:00am

Last month, nearly 900 attendees gathered for NAHAD’s 38th Annual Meeting and Convention at the Fontainebleau Miami Beach to reconnect with existing clients, engage with new customers, and take part in multiple educational sessions. The convention ran from May 15-18, and was kicked off with the “State of NAHAD” report by 2021-2022 by President Jeff […]


Source:WTWH
AtriCure Inc. (NASDAQ: ATRC) Stock Could Be An Option To Consider
Jun 25, 2022 12:30pm

AtriCure Inc. (NASDAQ:ATRC) shares, rose in value on Friday, 06/24/22, with the stock price up by 3.75% to the previous day’s close as strong demand from buyers drove the stock to $40.92. Actively observing the price movement in the last trading, the stock closed the session at $39.44, falling within a range of $39.08 and … AtriCure Inc. (NASDAQ: ATRC) Stock Could Be An Option To Consider Read More »


Source:Stocks Register
3Spine wins FDA IDE for spine implant
Jun 22, 2022 00:00am

3Spine announced today that it received FDA investigational device exemption (IDE) for its Motus spinal implant device. Chattanooga, Tennessee-based 3Spine designed the Motus device for use in the BalancedBack total joint replacement procedure. 3Spine’s BalancedBack procedure is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level […]


Source:WTWH
AtriCure: 5x Sales For A Series Of Impeding Losses (NASDAQ:ATRC)
Jun 13, 2022 15:44pm

AtriCure presents with numerous inflection points that sit on the distant horizon. Hence, we rate ATRC stock neutral. Click here to see why.


Source:Seeking Alpha
Investment - AtriCure, Inc. Expected to Announce Earnings of -$0.32 Per Share
Jun 04, 2022 12:19pm

Analysts expect AtriCure, Inc. to report earnings per share of for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for…


Source:Business Mag
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
Jun 01, 2022 12:00pm


Source:Kwhen Finance
Technology Innovation Institute Launches Pioneering Research Facility in Abu Dhabi for Key Industries in the Region
May 24, 2022 06:00am


Source:Kwhen Finance
AtriCure Inc. (NASDAQ: ATRC) Stock Dropped -27.50% Over A Month – Any Room To Run?
May 07, 2022 16:00pm

AtriCure Inc. (NASDAQ:ATRC)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting 1.17. At the close of trading, the stock’s price was $44.98, to imply a decrease of -9.15% or -$4.53 in intraday trading. The ATRC share’s 52-week high remains $89.18, putting it -98.27% down since that peak … AtriCure Inc. (NASDAQ: ATRC) Stock Dropped -27.50% Over A Month – Any Room To Run? Read More »


Source:Marketing Sentinel